On July 4, local time, WHO announced that it would stop using hydroxychloroquine and lopinavir/ritonavir in the "Unity Test". The results of the trial showed that hydroxychloroquine and lopinavir/ritonavir had little or no reduction in the mortality rate of patients with new coronary pneumonia. Previously, WHO launched the "Unity Trial" at the global level, aiming to compare the safety and effectiveness of several different drugs or drug combinations in the treatment of new coronary pneumonia, so as to find effective treatments as soon as possible. Earlier, US President Trump stated that he had regularly taken hydroxychloroquine drugs to prevent infection with the new coronavirus. (Edit Gao Yuhui)
Editor in charge: [Lu Yan]